Since late 2004, 7 novel antibiotics with activity against ESBL-E, CRE, and/or DTR P aeruginosa have been approved.
Samuel L. Aitken, PharmD, MPH; and Cornelius J. Clancy, MD
Advertisement
Articles by Samuel L. Aitken, PharmD, MPH; and Cornelius J. Clancy, MD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Contagion Live
1
Top Infectious Disease News Stories Week of November 29 - December 5
2
Early 2025 Influenza Vaccination Trends Following Prior Season and H3N2 Start
3
ACIP Votes on Hepatitis B Vaccine Marks More Confusion, No Supportive Safety Data, and Uncertainty of Public Health Policy
4
Petition Urges EPA to Halt Antibiotic and Antifungal Pesticide Use Over Resistance Risks
5
